Search

Your search keyword '"Thomas Fremming Dejgaard"' showing total 5 results
Start Over Author "Thomas Fremming Dejgaard"
5 results on '"Thomas Fremming Dejgaard"'

1. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

Author

Christian Stevns Hansen, Christian Seerup Frandsen, Jesper Fleischer, Dorte Vistisen, Jens Juul Holst, Lise Tarnow, Filip Krag Knop, Sten Madsbad, Henrik Ullits Andersen, and Thomas Fremming Dejgaard

Subjects
liraglutide, autonomic neuropathy, weight loss, insulin requirements, type 1 diabetes, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of −2.65 kg during the trial (95% CI: −4.60; −0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

Published
2019
Full Text
View/download PDF

2. GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes

Author

Sebastian Møller Nguyen Heimbürger, Bjørn Hoe, Chris Neumann Nielsen, Natasha Chidekel Bergman, Kirsa Skov-Jeppesen, Bolette Hartmann, Jens Juul Holst, Flemming Dela, Julie Overgaard, Joachim Størling, Tina Vilsbøll, Thomas Fremming Dejgaard, Jesper Foged Havelund, Vladimir Gorshkov, Frank Kjeldsen, Nils Joakim Færgeman, Martin Rønn Madsen, Mikkel B Christensen, and Filip Krag Knop

Subjects
Male, Cross-Over Studies, Proteome, Adipose Tissue, White, Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, Thermogenesis, Gastric Inhibitory Polypeptide, Fatty Acids, Nonesterified, Biochemistry, Diabetes Mellitus, Type 1, Endocrinology, Adipose Tissue, Brown, Humans, Bone Resorption, Transcriptome
Abstract

Context Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism. Objective We investigated the effects of a 6-day subcutaneous GIP infusion on circulating lipids, white adipose tissue (WAT), brown adipose tissue (BAT), hepatic fat content, inflammatory markers, respiratory exchange ratio (RER), and bone homeostasis in patients with type 1 diabetes. Methods In a randomized, placebo-controlled, double-blind, crossover study, 20 men with type 1 diabetes underwent a 6-day continuous subcutaneous infusion with GIP (6 pmol/kg/min) and placebo (saline), with an interposed 7-day washout period. Results During GIP infusion, participants (26 ± 8 years [mean ± SD]; BMI 23.8 ± 1.8 kg/m2; glycated hemoglobin A1c 51 ± 10 mmol/mol [6.8 ± 3.1%]) experienced transiently increased circulating concentrations of nonesterified fatty acid (NEFA) (P = 0.0005), decreased RER (P = 0.009), indication of increased fatty acid β-oxidation, and decreased levels of the bone resorption marker C-terminal telopeptide (P = 0.000072) compared with placebo. After 6 days of GIP infusion, hepatic fat content was increased by 12.6% (P = 0.007) and supraclavicular skin temperature, a surrogate indicator of BAT activity, was increased by 0.29 °C (P < 0.000001) compared with placebo infusion. WAT transcriptomic profile as well as circulating lipid species, proteome, markers of inflammation, and bone homeostasis were unaffected. Conclusion Six days of subcutaneous GIP infusion in men with type 1 diabetes transiently decreased bone resorption and increased NEFA and β-oxidation. Further, hepatic fat content, and supraclavicular skin temperature were increased without affecting WAT transcriptomics, the circulating proteome, lipids, or inflammatory markers.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results